Activity of pyocin S2 against Pseudomonas aeruginosa biofilms

Smith, K; Martin, L; Rinaldi, A; Rajendran, R; Ramage, G; Walker, D

Activity of pyocin S2 against Pseudomonas aeruginosa biofilms

Smith, K Martin, L

Rinaldi, A Rajendran, R Ramage, G Walker, D

Permalink

Publication Type:: Journal Article
Citation:: Antimicrobial Agents and Chemotherapy, 2012, 56 (3), pp. 1599 - 1601
Issue Date:: 2012-03-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published VersionAdobe PDF (852.44 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Smith, K	en_US
dc.contributor.author	Martin, L https://orcid.org/0000-0001-5897-0163	en_US
dc.contributor.author	Rinaldi, A	en_US
dc.contributor.author	Rajendran, R	en_US
dc.contributor.author	Ramage, G	en_US
dc.contributor.author	Walker, D	en_US
dc.date.issued	2012-03-01	en_US
dc.identifier.citation	Antimicrobial Agents and Chemotherapy, 2012, 56 (3), pp. 1599 - 1601	en_US
dc.identifier.issn	0066-4804	en_US
dc.identifier.uri	http://hdl.handle.net/10453/114839
dc.description.abstract	In cystic fibrosis patients, chronic lung infection with Pseudomonas aeruginosa and the associated decline in lung function are the major cause of mortality. In this report, we show that pyocin S2 displays potent activity against P. aeruginosa biofilms, thus representing a potentially improved therapeutic option. Using an invertebrate model of P. aeruginosa infection, we also show that pyocin S2 is highly active in vivo. Copyright © 2012, American Society for Microbiology. All Rights Reserved.	en_US
dc.relation.ispartof	Antimicrobial Agents and Chemotherapy	en_US
dc.relation.isbasedon	10.1128/AAC.05714-11	en_US
dc.subject.classification	Microbiology	en_US
dc.subject.mesh	Lung	en_US
dc.subject.mesh	Sputum	en_US
dc.subject.mesh	Animals	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Moths	en_US
dc.subject.mesh	Biofilms	en_US
dc.subject.mesh	Pseudomonas aeruginosa	en_US
dc.subject.mesh	Cystic Fibrosis	en_US
dc.subject.mesh	Aztreonam	en_US
dc.subject.mesh	Tobramycin	en_US
dc.subject.mesh	Pyocins	en_US
dc.subject.mesh	Anti-Bacterial Agents	en_US
dc.subject.mesh	Microscopy, Electron, Scanning	en_US
dc.subject.mesh	Larva	en_US
dc.subject.mesh	Child	en_US
dc.title	Activity of pyocin S2 against Pseudomonas aeruginosa biofilms	en_US
dc.type	Journal Article
utslib.citation.volume	3	en_US
utslib.citation.volume	56	en_US
utslib.for	0605 Microbiology	en_US
utslib.for	1108 Medical Microbiology	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Strength - ithree - Institute of Infection, Immunity and Innovation
utslib.copyright.status	open_access
pubs.issue	3	en_US
pubs.publication-status	Published	en_US
pubs.volume	56	en_US

Abstract:

In cystic fibrosis patients, chronic lung infection with Pseudomonas aeruginosa and the associated decline in lung function are the major cause of mortality. In this report, we show that pyocin S2 displays potent activity against P. aeruginosa biofilms, thus representing a potentially improved therapeutic option. Using an invertebrate model of P. aeruginosa infection, we also show that pyocin S2 is highly active in vivo. Copyright © 2012, American Society for Microbiology. All Rights Reserved.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/114839